Skip to main content
CABA logo

CABA · Cabaletta Bio, Inc.

Track CABA — free
$0.94 -0.07 (-7.32%) At close · Nov 20
Market Cap
$201.94M
Shares
215.72M
Volume · Nov 20 3.74M Avg daily vol (3M) 5.14M

Price & Indicators

 

Key stats

Close
$0.94
Fri 20 Nov
Open
$0.99
Fri 20 Nov
Average volume, 30 days
4.8M
shares a session
Short interest
38.4M
17.8% of shares · 8.2 days to cover
Day range
$0.93$1.04
Open $0.99 Close $0.94
52-week closing range
$0.94$4.15
Close $0.94 77.4% under the high
Short volume, last session
57%
Last earnings
Nov 10, 2026
Latest filing
10-Q · Nov 5
Price history
Jan 2020 to Nov 2026

Up next

Aug 15, 2029 Est · unconfirmed · in 142 wks

Latest documents

2026
Nov 18
Investor event
Rezacel shows favorable safety; pivotal myositis trials underway

Cabaletta Bio said its Rezacel showed a favorable safety profile in the first 71 patients treated. Of the first six dermatomyositis patients past one year, 100% were off immunosuppressants. The company is running a pivotal myositis program in adults and children, and had about $300 million in cash at the end of the third quarter, spending $40 to $50 million per quarter.

4 source passages
In the first 71 patients who we treated, we have what we would consider to be a favorable safety profile At one year, we reported that in the first six dermatomyositis patients who'd crossed the one-year time point, 100% of the patients were off of their immunosuppressants. So in order to focus, as we do, we are running a pivotal program in myositis in the adults and in children. We have about $300 million in the bank at the end of the third quarter, and we're spending about $40 to $50 million per quarter. Open the document at this passage
Nov 10
Investor event
Myositis BLA target moved after favorable CAR-T data

Cabaleta moved myositis BLA submission guidance to the first quarter of 28, alongside phase 1-2 data showing 94% of patients had no CRS or grade 1 CRS and 96% had no ICANs.

4 source passages
we're Cabaleta developing CAR-T therapies for patients with autoimmune disease. we moved our guidance to the first quarter of 28 for BLA submission, and we feel good about that. what we reported from the phase 1-2 data was the one-year outcomes of patients. 94% of patients have no CRS or grade 1 CRS of fever. 96% of patients have no ICANs. Open the document at this passage
Nov 9
Current report 8-K
Rese-cel shows durable responses across three autoimmune diseases

Cabaletta Bio, Inc. reported new Phase 1/2 rese-cel data: 100% (6/6) dermatomyositis patients sustained moderate-to-major responses through one year, 100% (5/5) biopsied lupus nephritis patients achieved DORIS remission, and 71% (5/7) systemic sclerosis patients achieved rCRISS-50.

Regulation FD disclosure, Other events Read from the first part of this long document
4 source passages
Cabaletta Bio, Inc. (Nasdaq: CABA), a late-stage clinical biotechnology company focused on developing and launching curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced new Phase 1/2 clinical data on resecabtagene autoleucel (rese-cel) to be presented in one oral and two poster presentations at the American College of Rheumatology (ACR) Convergence 2026 annual meeting in Orlando, FL. 100% (6/6) of patients maintained an immunomodulator-free, moderate-to-major Total Improvement Score (TIS) response through one year, with 83% (5/6) achieving that level as early as Week 16, the timepoint corresponding to the primary endpoint of the ongoing registrational dermatomyositis (DM) and antisynthetase syndrome (ASyS) cohort. 100% (5/5) of patients who underwent an optional repeat kidney biopsy after rese-cel infusion achieved the definition of remission in systemic lupus erythematosus (DORIS) off all immunomodulators and on no or low-dose steroids. 71% (5/7) of patients achieved rCRISS-50 at one year, with 86% (6/7) of patients achieving rCRISS-25 at the same timepoint. Open the document at this passage
Nov 5
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Myositis topline targeted for second half of 2027

Cabaletta Bio expects registrational myositis topline results in the second half of 2027 to support a potential BLA submission in the first quarter of 2028. It held $299.4 million in cash and cash equivalents as of September 30, 2026.

Net loss $53.05M Diluted EPS -$0.28
Read from the MD&A section
2 source passages
We anticipate reporting registrational myositis topline results in the second half of 2027 to support a potential BLA submission in the first quarter of 2028. As of September 30, 2026, we had $299.4 million in cash and cash equivalents. Open the document at this passage
Nov 5
Current report 8-K
Myositis BLA planned for 1Q28; cash runway into 1Q28

Cabaletta Bio plans a myositis BLA submission in 1Q28 after topline results in 2H27 and reported $299.4 million in cash as of September 30, 2026, extending its operational runway into 1Q28.

Financial results
3 source passages
RESET-Myositis® registrational adult topline results anticipated in 2H27 with BLA submission in 1Q28, including Phase 1/2 juvenile dermatomyositis data for potential PRV eligibility and Phase 1/2 adult durability data Operational runway extended into 1Q28 with $299.4 million cash position as of September 30, 2026 Cabaletta Bio Reports Third Quarter 2026 Financial Results and Provides Business Update Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$189.50M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-80.5%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$299.38M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+82.7%
Year over year · more shares
Price change (1Y)
-56.5%
Trailing year
Short interest
17.8%
Latest settlement · 8.2 days to cover
View all 125 metrics

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Strong Sell Momentum Very Weak Sentiment Bullish Fundamentals Fair Quant / Vol Very High
Market backdrop VIX 35.9 · fear Equity put/call 0.77
Technical
price trend
Strong Sell
50 / 200-day cross No cross
Price vs 200-day avg −66%
below
Price vs 50-day avg −46%
below
RSI (14) 26
oversold
MACD trend Negative
52-week position 0%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Weak
1-month return −36%
trailing
6-month return −75%
trailing
YTD return −57%
this year
Relative strength −65%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $2 › 200d $3 — 200d above 50d
Institutional flow Accumulating
+16% holders QoQ · +35 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
17.79% of shares out · ▼ -2.3% MoM · 8.2 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
165 holders — near 3-yr high, broad support
Squeeze score 70
high risk · 0–100
Fundamentals
Fair
EPS growth +10%
Y/Y
Free cash flow $-132.3M
Quant / Vol
risk profile
Very High
Volatility 85%
annualized · 1-yr
Max drawdown −77%
past year
ATR 15.0%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Strong Sell
4 · 3 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−66% Bearish
Price vs 50-day avg
−46% Bearish
RSI (14)
26 Neutral
MACD trend
Negative Bearish
52-week position
0% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross) No cross
50d $2 › 200d $3 — 200d above 50d
Institutional flow Accumulating
+16% holders QoQ · +35 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
17.79% of shares out · ▼ -2.3% MoM · 8.2 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
165 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $1 Now $1 · 0% Range high $4
vs 200-day avg -66% vs 50-day avg -46%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Cash from exercises of common stock warrants $115M July 1, 2026 to September 12, 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
CABA
Cabaletta Bio, Inc.
this stock
$201.94M -57.3% — — 17.8%
VRTX
Vertex Pharmaceuticals Inc
$130.58B +13.6% +46.2% 33.2 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
$95.24B +19.3% +20.8% 20.4 2.1%
MRNA
Moderna, Inc.
$78.90B +561.2% +4.3% — 8.2%
CSLLY
Csl Ltd
$62.17B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
165
% held
87.5%
Net QoQ
+30.8M sh
Top holder
JENNISON ASSOCIATES LLC
Held Float
View
Held by Funds
Fund positions
155
View
Short & Settlement
Short Interest Falling
Shares short
38.4M
Days to cover
8.2d
Change
-917.1K sh
View
Short Volume
Short vol %
57%
As of
Nov 20, 2026
Short Total
View
Fails to Deliver
FTD shares
35.9K
Value
$57.0K
As of
Oct 30, 2026
View
Off-Exchange
Off-exchange %
55.6%
Week of
Oct 12, 2026
Off-exch Lit
View
Financials
Financials
Net income (FY)
$-167.9M
EPS diluted
$-2.10
View
Filings
SEC Filings
Latest
Investor Event Transcript
Filed
Nov 18, 2026
This year
27

Cabaletta Bio said its Rezacel showed a favorable safety profile in the first 71 patients treated. Of the first six dermatomyositis patients past one year, 100% were off immunosuppressants. The company is running a pivotal myositis program in adults and children, and had about $300 million in cash at the end of the third quarter, spending $40 to $50 million per quarter.

View
Proposed Sales
Value
$592.7K
Shares
33.0K
Filed
Nov 20, 2023
View
Earnings & Events
Webcasts
Last webcast
Nov 18, 2026
View
Investor Relations
Latest news
Cabaletta Bio Presents New Rese-c…
Published
Nov 9, 2026
View

Performance

5D 20D 120D MTD YTD
CABA -26.9% -36.3% -74.6% -38.0% -57.3%
SPY -8.6% -9.2% -9.2% -8.7% +1.2%
vs SPY -18.3% -27.1% -65.4% -29.3% -58.4%
Key facts CIK 1759138 CUSIP 12674W109 13F (30d) 169 filings 157 filers Visit website Investor relations